Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368927 · ClinicalTrials.gov registry record · Phase 2
Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00368927: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00368927 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00368927, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying sulindac to see how well it works compared to a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sulindac may prevent lung cancer from forming in patients with bronchial dysplasia. It is not yet known whether sulindac is more effective than a placebo in preventing lung cancer in patients with bronchial dysplasia.
Interventions
- OTHER placebo
- DRUG sulindac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2006-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00368927
The ClinicalTrials.gov registry entry for NCT00368927 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00368927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00368927 about?
NCT00368927 is a clinical study titled "Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia". This randomized phase II trial is studying sulindac to see how well it works compared to a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sulindac ma...
What is the current status of trial NCT00368927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2006-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00368927?
The interventions under investigation include: placebo (OTHER), sulindac (DRUG).
Who is sponsoring clinical trial NCT00368927?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.